Insilico Medicine Partners With ASKA To Identify Targets
Insilico Medicine today announced a strategic research collaboration with ASKA Pharmaceutical to identify therapeutic targets for endometriosis, uterine fibroids and adenomyosis using Insilico's AI-driven PandaOmics and TargetPro platforms. The partnership combines ASKA's gynecological expertise with Insilico's target-identification models to accelerate preclinical validation and advance treatments for diseases affecting hundreds of millions, including an estimated 190 million women with endometriosis.
Scoring Rationale
Official company collaboration shows translational potential, but limited technical novelty and primarily press-release detail.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
